The neurobiology of the prader-willi phenotype of fragile x syndrome

Intractable and Rare Diseases Research

Volumn 5, Issue 4, 2016, Pages 255-261

  Muzar, Zukhrofi ^a,b   Lozano, Reymundo ^c   Kolevzon, Alexander ^c,d   Hagerman, Randi J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITAS MUHAMMADIYAH SUMATERA UTARA   (Indonesia)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d NONE

Author keywords

Autism; FMR1 gene; Fragile X syndrome (FXS); Growth hormone; Hyperphagia; IGF 1; Prader Willi phenotype

Indexed keywords

ARBACLOFEN; GANAXOLONE; HUMAN GROWTH HORMONE; INSULIN GROWTH FACTOR 1; METFORMIN; MINOCYCLINE; OXYTOCIN; SOMATOMEDIN; UNCLASSIFIED DRUG;

AUTISM; CLINICAL TRIAL (TOPIC); DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FRAGILE X SYNDROME; HORMONAL THERAPY; HUMAN; HYPERPHAGIA; NEUROBIOLOGY; NONHUMAN; OBESITY; PRADER WILLI SYNDROME; PROTEIN SECRETION; REVIEW; SATIETY; SLEEP DISORDERED BREATHING;

EID: 85030139865     PISSN: 21863644     EISSN: 2186361X     Source Type: Journal    
DOI: 10.5582/irdr.2016.01082     Document Type: Review

References (71)

1. Butler MG, Lee PDK, Whitman BY, editors. Management of Prader-Willi Syndrome. New York, NY: Springer New York; 2006. http://link.springer.com/10.1007/978-0-387-33536-0 (accessed September 26, 2016).
2. Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader-Willi syndrome. Genet Med. 2012; 14:10-26.
3. Butler MG. Prader-Willi Syndrome: Obesity due to genomic imprinting. Curr Genomics. 2011; 12:204-215.
4. Fernández E, Rajan N, Bagni C. The FMRP regulon: From targets to disease convergence. Front Neurosci. 2013; 7:191.
5. Tassone F, Iong KP, Tong T-H, Lo J, Gane LW, Berry-Kravis E, Nguyen D, Mu LY, Laffin J, Bailey DB, Hagerman RJ. FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. Genome Med. 2012; 4:100.
6. Nowicki ST, Tassone F, Ono MY, Ferranti J, Croquette MF, Goodlin-Jones B, Hagerman RJ. The Prader-Willi phenotype of fragile X syndrome. J Dev Behav Pediatr. 2007; 28:133-138.
7. Fryns JP, Haspeslagh M, Dereymaeker AM, Volcke P, Van den Berghe H. A peculiar subphenotype in the fra(X) syndrome: Extreme obesity-short stature-stubby hands and feet-diffuse hyperpigmentation. Further evidence of disturbed hypothalamic function in the fra(X) syndrome. Clin Genet. 1987; 32:388-392.
8. Schrander-Stumpel C, Gerver WJ, Meyer H, Engelen J, Mulder H, Fryns JP. Prader-Willi-like phenotype in fragile X syndrome. Clin Genet. 1994; 45:175-180.
9. de Vries BB, Fryns JP, Butler MG, Canziani F, Wesby-van Swaay E, van Hemel JO, Oostra BA, Halley DJ, Niermeijer MF. Clinical and molecular studies in fragile X patients with a Prader-Willi-like phenotype. J Med Genet. 1993; 30:761-766.
10. De Vries BB, Niermeijer MF. The Prader-Willi-like phenotype in fragile X patients: A designation facilitating clinical (and molecular) differential diagnosis. J Med Genet. 1994; 31:820.
11. McLennan Y, Polussa J, Tassone F, Hagerman R. Fragile x syndrome. Curr Genomics. 2011; 12:216-224.
12. HOEBEL BG, TEITELBAUM P. Hypothalamic control of feeding and self-stimulation. Science. 1962; 135:375377.
13. Berthoud H-R, Münzberg H. The lateral hypothalamus as integrator of metabolic and environmental needs: From electrical self-stimulation to opto-genetics. Physiol Behav. 2011; 104:29-39.
14. Jennings JH, Ung RL, Resendez SL, Stamatakis AM, Taylor JG, Huang J, Veleta K, Kantak PA, Aita M, Shilling-Scrivo K, Ramakrishnan C, Deisseroth K, Otte S, Stuber GD. Visualizing hypothalamic network dynamics for appetitive and consummatory behaviors. Cell. 2015; 160:516-527.
15. Berry-Kravis E, Knox A, Hervey C. Targeted treatments for fragile X syndrome. J Neurodev Disord. 2011; 3:193210.
16. Hagerman R, Lozano R, Hare E. Modulation of the GABAergic pathway for the treatment of fragile X syndrome. Neuropsychiatr Dis Treat. 2014; 10:17691779.
17. Lucignani G, Panzacchi A, Bosio L, Moresco RM, Ravasi L, Coppa I, Chiumello G, Frey K, Koeppe R, Fazio F. GABAa receptor abnormalities in Prader-Willi syndrome assessed with positron emission tomography and [11C]flumazenil. Neuroimage. 2004; 22:22-28.
18. Chai J-H, Locke DP, Greally JM, Knoll JHM, Ohta T, Dunai J, Yavor A, Eichler EE, Nicholls RD. Identification of four highly conserved genes between breakpoint hotspots BP1 and BP2 of the Prader-Willi/Angelman syndromes deletion region that have undergone evolutionary transposition mediated by flanking duplicons. Am J Hum Genet. 2003; 73:898-925.
19. Schenck A, Bardoni B, Moro A, Bagni C, Mandel JL. A highly conserved protein family interacting with the fragile X mental retardation protein (FMRP) and displaying selective interactions with FMRP-related proteins FXR1P and FXR2P. Proc Natl Acad Sci U S A. 2001; 98:8844-8849.
20. Bardoni B, Mandel J-L. Advances in understanding of fragile X pathogenesis and FMRP function, and in identification of X linked mental retardation genes. Curr Opin Genet Dev. 2002; 12:284-293.
21. Schenck A, Bardoni B, Langmann C, Harden N, Mandel JL, Giangrande A. CYFIP/Sra-1 controls neuronal connectivity in Drosophila and links the Rac1 GTPase pathway to the fragile X protein. Neuron. 2003; 38:887898.
22. De Rubeis S, Pasciuto E, Li KW, et al. CYFIP1 coordinates mRNA translation and cytoskeleton remodeling to ensure proper dendritic spine formation. Neuron. 2013; 79:1169-1182.
23. Pathania M, Davenport EC, Muir J, Sheehan DF, Lopez-Doménech G, Kittler JT. The autism and schizophrenia associated gene CYFIP1 is critical for the maintenance of dendritic complexity and the stabilization of mature spines. Transl Psychiatry. 2014; 4:e374.
24. Francis SM, Sagar A, Levin-Decanini T, Liu W, Carter CS, Jacob S. Oxytocin and vasopressin systems in genetic syndromes and neurodevelopmental disorders. Brain Res. 2014; 1580:199-218.
25. Swaab DF, Purba JS, Hofman MA. Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: A study of five cases. J Clin Endocrinol Metab. 1995; 80:573-579.
26. Tauber M, Mantoulan C, Copet P, Jauregui J, Demeer G, Diene G, Rogé B, Laurier V, Ehlinger V, Arnaud C, Molinas C, Thuilleaux D. Oxytocin may be useful to increase trust in others and decrease disruptive behaviours in patients with Prader-Willi syndrome: A randomised placebo-controlled trial in 24 patients. Orphanet J Rare Dis. 2011; 6:47.
27. Hall SS, Lightbody AA, McCarthy BE, Parker KJ, Reiss AL. Effects of intranasal oxytocin on social anxiety in males with fragile X syndrome. Psychoneuroendocrinology. 2012; 37:509-518.
28. Dawson G, Jones EJH, Merkle K, Venema K, Lowy R, Faja S, Kamara D, Murias M, Greenson J, Winter J, Smith M, Rogers SJ, Webb SJ. Early behavioral intervention is associated with normalized brain activity in young children with autism. J Am Acad Child Adolesc Psychiatry. 2012; 51:1150-1159.
29. Tolmie J. Fragile X syndrome - diagnosis, treatment and research. J Med Genet. 2002; 39:783.
30. Hagerman RJ, Berry-Kravis E, Kaufmann WE, Ono MY, Tartaglia N, Lachiewicz A, Kronk R, Delahunty C, Hessl D, Visootsak J, Picker J, Gane L, Tranfaglia M. Advances in the treatment of fragile X syndrome. Pediatrics. 2009; 123:378-390.
31. Indah Winarni T, Chonchaiya W, Adams E, Au J, Mu Y, Rivera SM, Nguyen DV, Hagerman RJ. Sertraline may improve language developmental trajectory in young children with fragile x syndrome: A retrospective chart review. Autism Res Treat. 2012; 2012:104317.
32. Nussbaum LA, Dumitraşcu V, Tudor A, Grâdmaru R, Andreescu N, Puiu M. Molecular study of weight gain related to atypical antipsychotics: Clinical implications of the CYP2D6 genotype. Rom J Morphol Embryol. 2014; 55:877-884.
33. Berry-Kravis EM, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K, Mu Y, Nguyen DV, Gonzalez-Heydrich J, Wang PP, Carpenter RL, Bear MF, Hagerman RJ. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: A randomized, controlled, phase 2 trial. Sci Transl Med. 2012; 4:152ra127.
34. Berry-Kravis E. Arbaclofen In Fragile X Syndrome: Results Of Phase 3 Trials and FXCRC Analysis Of Arbaclofen Respons. In: National Fragile X Foundation, 14th International Fragile X Conference, Orange County, CA. USA, 2014.
35. Leigh MJS, Nguyen DV, Mu Y, Winarni TI, Schneider A, Chechi T, Polussa J, Doucet P, Tassone F, Rivera SM, Hessl D, Hagerman RJ. A randomized doubleblind, placebo-controlled trial of minocycline in children and adolescents with fragile X syndrome. J Dev Behav Pediatr. 2013; 34:147-155.
36. Lozano R, Hagerman RJ. Treatment of Neurodevelopmental Disorders. In: Hagerman RJ, Hendren RL, editors. Treatment of neurodevelopmental disorders: Targeting neurobiological mechanisms. Oxford University Press, Oxford, UK, 2014.
37. Deal CL, Tony M, Hoybye C, Allen DB, Tauber M, Christiansen JS, 2011 Growth hormone in prader-Willi Syndrome clinical care guidelines workshop participants. Growth hormone research society workshop summary: Consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab. 2013; 98:E1072-E1087.
38. Miller J, Strong T, Heinemann J. Medication Trials for Hyperphagia and Food-Related Behaviors in Prader-Willi Syndrome. Diseases. 2015; 3:78-85.
39. Angulo MA, Castro-Magana M, Lamerson M, Arguello R, Accacha S, Khan A. Final adult height in children with Prader-Willi syndrome with and without human growth hormone treatment. Am J Med Genet A. 2007; 143A:1456-1461.
40. Carrel AL, Myers SE, Whitman BY, Eickhoff J, Allen DB. Long-term growth hormone therapy changes the natural history of body composition and motor function in children with prader-willi syndrome. J Clin Endocrinol Metab. 2010; 95:1131-1136.
41. Butler MG, Smith BK, Lee J, Gibson C, Schmoll C, Moore WV, Donnelly JE. Effects of growth hormone treatment in adults with Prader-Willi syndrome. Growth Horm IGF Res. 2013; 23:81-87.
42. Siemensma EPC, Tummers-de Lind van Wijngaarden RFA, Festen DA, et al. Beneficial effects of growth hormone treatment on cognition in children with Prader-Willi syndrome: A randomized controlled trial and longitudinal study. J Clin Endocrinol Metab. 2012; 97:2307-2314.
43. Sanchez-Ortiga R, Klibanski A, Tritos NA. Effects of recombinant human growth hormone therapy in adults with Prader-Willi syndrome: A meta-analysis. Clin Endocrinol (Oxf). 2012; 77:86-93.
44. Mogul HR, Lee PDK, Whitman BY, Zipf WB, Frey M, Myers S, Cahan M, Pinyerd B, Southren AL. Growth hormone treatment of adults with Prader-Willi syndrome and growth hormone deficiency improves lean body mass, fractional body fat, and serum triiodothyronine without glucose impairment: Results from the United States multicenter trial. J Clin Endocrinol Metab. 2008; 93:1238-1245.
45. Maya-Vetencourt JF, Baroncelli L, Viegi A, Tiraboschi E, Castren E, Cattaneo A, Maffei L. IGF-1 restores visual cortex plasticity in adult life by reducing local GABA levels. Neural Plast. 2012; 2012:250421.
46. Zhang W, Xu C, Tu H, Wang Y, Sun Q, Hu P, Rondard P, Liu J. GABAB receptor upregulates fragile X mental retardation protein expression in neurons. Sci Rep. 2015; 5:10468.
47. McLennan Y, Polussa J, Tassone F, Hagerman R. Fragile x syndrome. Curr Genomics. 2011; 12:216-224.
48. Davis RL. Olfactory memory formation in Drosophila: From molecular to systems neuroscience. Annu Rev Neurosci. 2005; 28:275-302.
49. Griffith LC, Ejima A. Multimodal sensory integration of courtship stimulating cues in Drosophila melanogaster. Ann N Y Acad Sci. 2009; 1170:394-398.
50. Joiner M., Griffith LC. CaM kinase II and visual input modulate memory formation in the neuronal circuit controlling courtship conditioning. J Neurosci Off J Soc Neurosci. 1997; 17:9384-9391.
51. McGuire SE, Le PT, Osborn AJ, Matsumoto K, Davis RL. Spatiotemporal rescue of memory dysfunction in Drosophila. Science. 2003; 302:1765-1768.
52. Nassel DR, Kubrak OI, Liu Y, Luo J, Lushchak O V Factors that regulate insulin producing cells and their output in Drosophila. Front Physiol. 2013; 4:252.
53. Qin M, Kang J, Smith CB. Increased rates of cerebral glucose metabolism in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A. 2002; 99:15758-15763.
54. Monyak RE, Emerson D, Schoenfeld BP, Zheng X, Chambers DB, Rosenfelt C, Langer S, Hinchey P, Choi CH, McDonald TV, Bolduc FV, Sehgal A, McBride SM, Jongens TA. Insulin signaling misregulation underlies circadian and cognitive deficits in a Drosophila fragile X model. Mol Psychiatry. 2016; doi: 10.1038/mp.2016.51.
55. McDonagh MS, Selph S, Ozpinar A, Foley C. Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger. JAMA Pediatr. 2014; 168:178-184.
56. Ying MA, Maruschak N, Mansur R, Carvalho AF, Cha DS, McIntyre RS. Metformin: Repurposing opportunities for cognitive and mood dysfunction. CNS Neurol Disord Drug Targets. 2014; 13:1836-1845.
57. Ng TP, Feng L, Yap KB, Lee TS, Tan CH, Winblad B. Long-term metformin usage and cognitive function among older adults with diabetes. J Alzheimer's Dis JAD. 2014; 41:61-68.
58. Sun W, Zeng C, Liao L, Chen J, Wang Y Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obesity. Curr Med Res Opin. 2016; 32:1389-1396.
59. Roumie CL, Greevy RA, Grijalva CG, Hung AM, Liu X, Griffin MR. Diabetes treatment intensification and associated changes in HbA1c and body mass index: A cohort study. BMC Endocr Disord. 2016; 16:32.
60. Jin J, Gu H, Anders NM, Ren T, Jiang M, Tao M, Peng Q, Rudek MA, Duan W. Metformin protects cells from mutant huntingtin toxicity through activation of AMPK and modulation of mitochondrial dynamics. Neuromolecular Med. 2016; doi: 10.1007/s12017-016-8412-z
61. Luo T, Nocon A, Fry J, Sherban A, Rui X, Jiang B, Xu XJ, Han J, Yan Y, Yang Q, Li Q, Zang M. AMPK activation by metformin suppresses abnormal adipose tissue extracellular matrix remodeling and ameliorates insulin resistance in obesity. Diabetes. 2016; 65:22952310.
62. Anabtawi A, Miles JM. Metformin: Non-glycemic effects and potential novel indications. Endocr Pract. 2016; doi: 10.4158/EP151145.RAR
63. Rattan R, Ali Fehmi R, Munkarah A. Metformin: An emerging new therapeutic option for targeting cancer stem cells and metastasis. J Oncol. 2012; 2012:928127.
64. Miller JL, Linville TD, Dykens EM. Effects of metformin in children and adolescents with Prader-Willi syndrome and early-onset morbid obesity: A pilot study. J Pediatr Endocrinol Metab JPEM. 2014; 27:23-29.
65. Kanber D, Giltay J, Wieczorek D, Zogel C, Hochstenbach R, Caliebe A, Kuechler A, Horsthemke B, Buiting K. A paternal deletion of MKRN3, MAGEL2 and NDN does not result in Prader-Willi syndrome. Eur J Hum Genet. 2009; 17:582-590.
66. Boccaccio I, Glatt-Deeley H, Watrin F, Roeckel N, Lalande M, Muscatelli F. The human MAGEL2 gene and its mouse homologue are paternally expressed and mapped to the Prader-Willi region. Hum Mol Genet. 1999; 8:2497-2505.
67. Dombret C, Nguyen T, Schakman O, Michaud JL, Hardin-Pouzet H, Bertrand MJ, De Backer O. Loss of Maged1 results in obesity, deficits of social interactions, impaired sexual behavior and severe alteration of mature oxytocin production in the hypothalamus. Hum Mol Genet. 2012; 21:4703-4717.
68. Muscatelli F, Abrous DN, Massacrier A, Boccaccio I, Le Moal M, Cau P, Cremer H. Disruption of the mouse Necdin gene results in hypothalamic and behavioral alterations reminiscent of the human Prader-Willi syndrome. Hum Mol Genet. 2000; 9:3101-3110.
69. Lavi-Itzkovitz A, Tcherpakov M, Levy Z, Itzkovitz S, Muscatelli F, Fainzilber M. Functional Consequences of Necdin Nucleocytoplasmic Localization. PLoS One. 2012; 7:e33786.
70. Tsai TF, Jiang YH, Bressler J, Armstrong D, Beaudet AL. Paternal deletion from Snrpn to Ube3a in the mouse causes hypotonia, growth retardation and partial lethality and provides evidence for a gene contributing to Prader-Willi syndrome. Hum Mol Genet. 1999; 8:1357-1364.
71. Haqq AM, Grambow SC, Muehlbauer M, Newgard CB, Svetkey LP, Carrel AL, Yanovski JA, Purnell JQ, Freemark M. Ghrelin concentrations in Prader-Willi syndrome (PWS) infants and children: Changes during development. Clin Endocrinol (Oxf). 2008; 69:911-920.